is semaglutide dangerous
In trials, tirzepatide achieved 22% average weight loss - about 30% more than semaglutide - prompting many patients to switch. Both drugs belong to the GLP-1 receptor agonist class, but tirzepatide’s added GIP activity delivers stronger appetite control and lean-mass preservation. As a result, clinicians see a growing pipeline
is semaglutide dangerous
People switch from semaglutide to tirzepatide because tirzepatide delivers up to 15% greater weight loss while maintaining similar cardiovascular protection. The newer drug also offers a slightly different dosing schedule, which some patients find easier to incorporate into daily life. In the SURPASS-2 trial, tirzepatide produced an average 15% larger
is semaglutide dangerous
Semaglutide is generally safe for most patients, but rare complications - such as a five-fold increase in vision-loss risk - require careful monitoring. The drug’s popularity has surged as clinicians prescribe it for obesity and type-2 diabetes, yet the rapid expansion of GLP-1 use has exposed gaps in patient
is semaglutide dangerous
In a head-to-head trial, tirzepatide produced 15% greater ≥10% weight loss than semaglutide, prompting many patients to switch for stronger results. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions. Why Do People Switch
is semaglutide dangerous
In the SURMOUNT-5 trial, 28% more participants who switched to tirzepatide lost ≥15% of body weight compared with those who stayed on semaglutide. Both drugs are GLP-1 receptor agonists, but tirzepatide adds GIP activity, which can deepen weight loss. Switching is not automatic; clinicians weigh efficacy, side-effects, and patient goals